Case Report: mTOR inhibitor treatment for epithelioid angiomyolipoma harboring biallelic TSC2 mutations

Key Points

• mTOR inhibitor treatment shows promise for managing actionable alterations in epithelioid angiomyolipoma.
• The presence of biallelic TSC2 mutations could guide personalized therapeutic choices effectively.
• Comprehensive genomic profiling was utilized to identify TSC2 mutations, indicating tailored treatment strategies.
• This case emphasizes the need for personalized therapy approaches in patients with specific genetic alterations.

Abstract